Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:6170
Name ovarian carcinosarcoma
Definition A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has_material_basis_in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00954174 Phase III Carboplatin + Paclitaxel Ifosfamide + Paclitaxel Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer Unknown status USA 1
NCT00989651 Phase I Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed USA 0
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Completed USA 0
NCT02432378 Phase Ib/II Celecoxib + Cisplatin + Interferon alpha-2b + Rintatolimod Celecoxib + Cisplatin Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Recruiting USA 0
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Completed USA 0
NCT03462212 Phase Ib/II Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) Recruiting ITA 0
NCT03574779 Phase II Bevacizumab + Dostarlimab-gxly + Niraparib Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL) Active, not recruiting USA | TUR | ESP | CAN 0
NCT03602859 Phase III Dostarlimab-gxly + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL 2
NCT03610490 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT03651206 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Doxorubicin + Gemcitabine + Paclitaxel Niraparib Dostarlimab-gxly + Niraparib Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN) Active, not recruiting FRA 0
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Active, not recruiting USA | TUR | ROU | POL | ITA | HUN | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BGR | BEL | AUT 4
NCT03924245 Phase Ib/II Entinostat Entinostat + Olaparib Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Terminated USA 0
NCT04274426 Phase II Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA) Active, not recruiting DEU 0
NCT04931342 Phase II Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Active, not recruiting USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS 2
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT05559879 Phase Ib/II Cabozantinib + Dostarlimab-gxly Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma Recruiting USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05619913 Phase II Eribulin Eribulin + Pembrolizumab EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH) Recruiting GBR | CAN | AUS 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DNK | CHE 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0